Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Accumulated Expenses (2016 - 2023)

Lineage Cell Therapeutics has reported Other Accumulated Expenses over the past 13 years, most recently at $1000.0 for Q2 2023.

  • For Q2 2023, Other Accumulated Expenses fell 90.0% year-over-year to $1000.0; the TTM value through Jun 2023 reached $1000.0, down 90.0%, while the annual FY2021 figure was $178000.0, 1877.78% up from the prior year.
  • Other Accumulated Expenses for Q2 2023 was $1000.0 at Lineage Cell Therapeutics, down from $37000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $492000.0 in Q2 2021 and troughed at $1000.0 in Q2 2023.
  • A 5-year average of $78187.5 and a median of $31000.0 in 2022 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: soared 1877.78% in 2021 and later plummeted 97.97% in 2022.
  • Year by year, Other Accumulated Expenses stood at $4000.0 in 2019, then soared by 125.0% to $9000.0 in 2020, then soared by 1877.78% to $178000.0 in 2021, then crashed by 85.96% to $25000.0 in 2022, then crashed by 96.0% to $1000.0 in 2023.
  • Business Quant data shows Other Accumulated Expenses for LCTX at $1000.0 in Q2 2023, $37000.0 in Q1 2023, and $25000.0 in Q3 2022.